-+ 0.00%
-+ 0.00%
-+ 0.00%

LANTHEUS RECEIVES FINAL FDA APPROVAL FOR BRAVNETSA™ (LUTETIUM LU 177 DOTATATE), THE ONLY RADIOPHARMACEUTICAL FDA HAS DETERMINED TO BE BIOEQUIVALENT AND THERAPEUTICALLY EQUIVALENT TO LUTATHERA® FOR THE TREATMENT OF GEP-NETS

Reuters·09/22/2026 12:00:02

Please log in to view news